



Updates on Novel Antimicrobial Agents and Strategies Against Pathogenic Bacteria

Guest Editor:

Dr. Marco Maria D'Andrea

Department of Biology, University
of "Tor Vergata", Rome, Italy

Deadline for manuscript
submissions:

closed (30 September 2019)

Message from the Guest Editor

Dear Colleagues,

The problem of antibiotic resistance in bacterial pathogens has reached alarming levels, with the emergence and diffusion at worldwide scale of strains displaying complex antibiotic resistance phenotypes which seriously impede the effective treatment of some bacterial infections. A number of international bodies, such as WHO and the American Center for Disease Control and Prevention, forecast that this 'antibiotic resistance crisis' will lead to the death of several million people per year in the 21st century. Therefore, there is an urgent need to develop novel antibiotics and innovative antimicrobial approaches. The issue aims to provide an update about original approaches to fight bacterial pathogens. It is expected that the issue will collect research articles on new molecules with antimicrobial activity, including new conventional antibiotics of either synthetic or natural origin, modified drugs with augmented potency to be used alone or in synergy, innovative alternatives such bacteriophages or components, enzybiotics, and probiotics able to displace the pathogenic microflora.

Dr. Marco Maria D'Andrea

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)